Nuvectis Pharma Inc (NVCT) 13F Holdings Overview (Q2 2026)

Nuvectis Pharma (NVCT) reported two connected moves in this 8-K: it shut down its earlier at-the-market (ATM) stock-sale program on July 20, 2026, then set up a replacement on August 21 by signing a new Open Market Sale Agreement with Jefferies LLC as sales agent. Alongside the deal, the company filed a fresh shelf registration statement covering $200 million in securities, giving it the option to sell shares into the market gradually through Jefferies whenever it chooses. Nothing is guaranteed to be sold — Jefferies works on a commercially-reasonable-efforts basis and earns a commission of up to 3% on gross proceeds. In short, the old fundraising tap was switched off and replaced with a bigger one.

Nuvectis Pharma (NVCT) put out a press release on August 4, 2026, giving a corporate update and reporting its financial results for the second quarter ended June 30, 2026. This 8-K is just the formal notice attaching that press release as Exhibit 99.1 — the excerpt doesn't lay out any specific numbers, so the actual results live in the release itself.

Nuvectis Pharma entered into an underwriting agreement to sell 5 million shares of common stock at $20 per share in a firm commitment public offering. The company expects to net about $93 million from the sale, or up to $107 million if the underwriters exercise an option to buy an additional 750,000 shares. The offering is set to close on July 1, 2026.

No AI summary for this filing type